Fig. 2: 89ZED88082A uptake in nonirradiated tumor lesions.
From: Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
a, Pretreatment uptake in 266 lesions day 2 after tracer injection, ordered by increasing geometric mean SUVmax per patient, visualizing lesion size and site, and aorta background uptake. ∅, diameter. μ, mean. b, Axial views PET/CT scans, arrows indicate lesions. (i) High, heterogeneous uptake in dMMR duodenal tumor. (ii) Uptake in a triple-negative right breast cancer lesion, moderate uptake in pleural and no to minor uptake in lung lesions. (iii) Minor uptake in perivesical dMMR urothelial cell cancer lesion pretreatment increased with rim pattern during treatment (iv). c, Violin plot SUVmax in lesions (n = 212) per site (lymph nodes n = 99, liver n = 35, bone n = 17, lung n = 42, skin n = 19). d, Violin plot of SUVmax in patients with pMMR (n = 25) and dMMR tumors (n = 9). e, Violin plot of SUVmax in lesions with desert (n = 15) and nondesert (n = 19) immune phenotype before and during treatment in 24 patients. c–e, Violin plots with bottom and top 1% of SUVmax values truncated (c and d, not for e); colored dots are the geometric means per patient (d) or lesion (e); black vertical lines are geometric mean SUVmax 95% CI; white dots within black lines and values below the violin plot the actual geometric means. Two-sided nominal P values were derived from linear mixed models taking clustering within patients (and, if applicable, lesions) into account, using a Wald test under restricted maximum likelihood for three of higher-level factors (c) or a likelihood ratio test under maximum likelihood for two-level factors (d,e). SqCC, squamous cell carcinoma; OCCC, ovarian clear cell carcinoma; HCC, hepatocellular carcinoma; UP, unknown primary.
